Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

The company reported difficulties ahead for its immunodiagnostics business in China in the wake of changes in late April related to the country's Diagnosis-Related Groups (DRG) policy on hospital lab ...

Last week, readers were most interested in a story about Roche's blood-based Alzheimer's test getting CE marking.

The deal brings together Promega's Maxwell automated nucleic acid extraction system and Longhorn's viral molecular transport media.

The company raised its full-year revenue guidance slightly due to changing foreign exchange rates but lowered its full-year EPS guidance.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.